Intermittent tri-weekly docetaxel plus bicalutamide in patients with castration-resistant prostate cancer: A single-arm prospective study using a historical control for comparison

Asian Journal of Andrology

Volumn 15, Issue 6, 2013, Pages 773-779

  Li, Yun Fei ^a,b   Zhang, Shao Feng ^b   Zhang, Tao Tao ^b   Li, Lei ^a   Gan, Wei ^b   Jia, Hong Tao ^b   Xie, Sheng ^b   Ji, Hui Hua ^b   He, Da Lin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

androgen; chemotherapy; docetaxel; prostate cancer; safety

Indexed keywords

BICALUTAMIDE; DEXAMETHASONE; DOCETAXEL; FLUTAMIDE; GONADORELIN AGONIST; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ALLERGIC REACTION; ALOPECIA; ANDROGEN DEPRIVATION THERAPY; ANEMIA; ARTICLE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; HOT FLUSH; HUMAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUALITY OF LIFE; VOMITING;

AGED; AGED, 80 AND OVER; ANILIDES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MIDDLE AGED; NITRILES; ORCHIECTOMY; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TAXOIDS; TOSYL COMPOUNDS;

EID: 84887243236     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2013.89     Document Type: Article

References (39)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nature reviews. Cancer 2001; 1: 34-45. (Pubitemid 33741879)
3. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339: 1036-42. (Pubitemid 28457865)
4. Pienta KJ, Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 2006; 12: 1665-71.
5. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12. (Pubitemid 39315317)
6. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 242-5.
7. Lin AM, Ryan CJ, Small EJ. Intermittent chemotherapy for metastatic hormone refractory prostate cancer. Crit Rev Oncol Hematol 2007; 61: 243-54. (Pubitemid 46329430)
8. Madan RA, Pal SK, Sartor O, Dahut WL. Overcoming chemotherapy resistance in prostate cancer. Clin Cancer Res 2011; 17: 3892-902.
9. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS et al. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer 2008; 112: 326-30.
10. Tormey DC, Weinberg VE, Leone LA, Glidewell OJ, Perloff M et al. A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer. A Cancer and Leukemia Group B study. Am J Clin Oncol 1984; 7: 231-9. (Pubitemid 14112249)
11. Maughan TS, James RD, Kerr DJ, Ledermann JA, Seymour MT et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet 2003; 361: 457-64. (Pubitemid 36173710)
12. Muss HB, Case LD, Richards F, White DR, Cooper MR et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med 1991; 325: 1342-8.
13. Cara S, Tannock IF. Retreatment of patients with the same chemotherapy: implications for clinical mechanisms of drug resistance. Ann Oncol 2001; 12: 23-7. (Pubitemid 32162444)
14. Tannock IF. Tumor physiology and drug resistance. Cancer Metastasis Rev 2001; 20: 123-32. (Pubitemid 34074688)
15. Norton L. Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy. Oncologist 2005; 10: 370-81. (Pubitemid 40993565)
16. Davis AJ, Tannock IF. Tumor physiology and resistance to chemotherapy: repopulation and drug penetration. Cancer Treat Res 2002; 112: 1-26.
17. Eymard JC, Oudard S, Gravis G, Ferrero JM, Theodore C et al. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJU Int 2010; 106: 974-8.
18. Kreis W, Budman DR, Fetten J, Gonzales AL, Barile B et al. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol 1999; 10: 33-8. (Pubitemid 29090589)
19. Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM. Intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer 2003; 89: 968-70. (Pubitemid 37239196)
20. Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM. Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer 2004; 91: 1425-7. (Pubitemid 39486342)
21. Miller E, Wulfing C, Lehmann J, Johannsen M, Heidenreich A et al. Weekly docetaxel plus estramustine for hormone-refractory prostate cancer (HRPC) with intermittent repetition: Preliminary results of a multicenter phase II study (AUO AP33/02). J Clin Oncol 2005; 23: 4613.
22. Lee SO, Lou W, Hou M, de Miguel F, Gerber L et al. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res 2003; 9: 370-6. (Pubitemid 36109754)
23. Sakai I, Miyake H, Terakawa T, Fujisawa M. Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model. Cancer Sci 2011; 102: 769-75.
24. Inoue T, Ogawa O. Role of signaling transduction pathways in development of castration-resistant prostate cancer. Prostate Cancer 2011; 2011: 647987.
25. Gregory CW, Johnson RT, Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001; 61: 2892-8. (Pubitemid 32691931)
26. Waltering KK, Wallen MJ, Tammela TL, Vessella RL, Visakorpi T. Mutation screening of the androgen receptor promoter and untranslated regions in prostate cancer. Prostate 2006; 66: 1585-91. (Pubitemid 44646350)
27. Chen T, Wang LH, Farrar WL. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res 2000; 60: 2132-5. (Pubitemid 30225173)
28. Joyce R, Fenton MA, Rode P, Constantine M, Gaynes L et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 1998; 159: 149-53. (Pubitemid 27525592)
29. Kucuk O, Fisher E, Moinpour CM, Coleman D, Hussain MH et al. Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235). Urology 2001; 58: 53-8. (Pubitemid 32633935)
30. Kliment J. Words of wisdom. Re: Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer. Lodde M, Lacombe L, Fradet Y. Eur Urol 2011; 59: 1066-7.
31. Gravis G, Fizazi K, Joly F, Oudard S, Priou F et al. PSA response and early PSA progression evaluated in patients randomized in a phase III trial comparing androgen-deprivation therapy (ADT) plus docetaxel versus ADT alone in hormonenaive metastatic prostate cancer (GETUG-AFU 15/0403). J Clin Oncol 2011; 29(Suppl 7): abstr 10.
32. Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y et al. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer. BJU Int 2012; 110: 1149-55.
33. Miura N, Numata K, Kusuhara Y, Shirato A, Hashine K et al. Docetaxel-prednisolone combination therapy for Japanese patients with hormone-refractory prostate cancer: a single institution experience. Jpn J Clin Oncol 2010; 40: 1092-8.
34. Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S et al. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 2008; 180: 921-7.
35. Soga N, Kato M, Nishikawa K, Hasegawa Y, Yamada Y et al. Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients. Int J Clin Oncol 2009; 14: 130-5.
36. Soloway MS, Schellhammer PF, Smith JA, Chodak GW, Vogelzang NJ et al. Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II noncomparative multicenter trial evaluating safety, efficacy and long-term endocrine effects of monotherapy. J Urol 1995; 154: 2110-4.
37. Kolvenbag GJ, Blackledge GR. Worldwide activity and safety of bicalutamide: a summary review. Urology 1996; 47: 70-9; discussion 80-4. (Pubitemid 126691289)
38. Mountzios I, Bournakis E, Efstathiou E, Varkaris A, Wen S et al. Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer. Urology 2011; 77: 682-7.
39. Zaghloul HA, Murillo JR. Treatment given near the end of life in castration-resistant prostate cancer. Am J Hosp Palliat Med 2012; 29: 536-40.